
SIBO and IBS share symptoms, but clinicians ask different diagnostic questions. Learn how symptom assessment and breath testing fit together.

On November 3, 2026, Precision Digestive published an explainer about why SIBO and IBS can share symptoms without being interchangeable diagnoses. Attributed to Dr. Meet Parikh, DO, it emphasizes that recurring digestive problems call for clinical evaluation rather than self-labeling.
Before this publication, the clinical starting point was already broader than matching symptoms to a name. Penn Medicine describes irritable bowel syndrome, or IBS, as a symptom-based disorder involving abdominal pain and changes in bowel movements. It says clinicians generally diagnose IBS from symptoms and may use tests to look for other conditions.
Penn Medicine lists gas and fullness among common IBS symptoms. Bloating, diarrhea and constipation also appear in its description. These are recognizable experiences for readers, but the medical assessment concerns the recurring pattern rather than whether someone recognizes an item on a list.
Small intestinal bacterial overgrowth, or SIBO, raises a different question. As Precision Digestive explains, clinicians investigate whether bacterial overgrowth in the small intestine may be contributing to symptoms. Its article describes an overlap with IBS that includes abdominal pain and bloating as well as gas and altered bowel habits.
The established distinction is therefore about the question being asked. An IBS assessment considers a pattern of pain and bowel changes. A SIBO investigation considers bacterial overgrowth as a possible contributor. Penn Medicine includes SIBO among the other conditions clinicians may check for when assessing someone with IBS symptoms.
For readers comparing descriptions online, this distinction matters more than finding the closest symptom match. The descriptions share too much ground for a checklist to reliably separate them. The relevant next question is how a clinician will interpret the person's recurring symptoms and decide what further assessment would be useful.
The value of the November 3 explainer is the distinction it draws between assessing a symptom pattern and investigating a possible contributor. It does not ask readers to replace an IBS label with a SIBO label. Instead, its emphasis is on understanding why similar experiences can lead clinicians to consider different questions.
According to Penn Medicine, IBS is usually diagnosed from symptoms. Abdominal pain and changes in bowel movements are central to that description. This makes the account of what keeps happening an important part of the assessment, rather than background information that becomes irrelevant once testing enters the conversation.
The useful distinction is between describing an experience and interpreting its cause. “Bloating keeps returning” describes a symptom. “I have SIBO” assigns an explanation. Precision Digestive's central message is that the second statement does not follow automatically from the first, even when an online description sounds familiar.
A clinical conversation can begin with the features covered by both sources: pain, bloating and gas. It can also address diarrhea or constipation and how symptoms relate to bowel movements. Those details describe the problem without requiring the person experiencing it to settle the diagnosis beforehand.
For readers seeking clearer language for bowel changes, DigestGenius's guide to describing stool form without overinterpreting it offers related educational context. The purpose of that description is communication, not choosing between diagnostic labels.
Precision Digestive describes glucose or lactulose breath testing as one way clinicians may investigate SIBO in people with IBS symptoms. In the test it describes, a person drinks a sugar solution. Breath samples are then collected at intervals and measured for gases such as hydrogen or methane.
This is a different task from assessing the symptom pattern used in an IBS evaluation. The clinician is gathering information relevant to possible bacterial overgrowth. Understanding that purpose makes the proposed test easier to discuss: what question is it intended to answer, and how will the result fit with the symptoms?
The explainer also cites the 2020 American College of Gastroenterology guideline as suggesting glucose or lactulose breath testing for SIBO in patients with IBS. That is the explainer's account of the guideline. It provides context for why a clinician might consider testing rather than establishing that every person with bloating needs the same investigation.
The practical change in perspective is modest but useful. A test should have a defined role in an assessment. The question is not simply whether testing is available, but what information the clinician expects it to add to the particular symptom pattern under discussion.
The publication is a clinical explainer rather than a new research study. Its contribution is educational: it brings existing diagnostic approaches into one discussion. It does not establish that SIBO explains IBS generally or announce a new dietary guideline.
Breath testing also has interpretive limits. It provides indirect evidence through measured gases rather than directly establishing every cause of the symptoms. Related Precision Digestive guidance cautions that a positive result does not explain everything and a negative result does not necessarily settle the question. Factors beyond bacterial overgrowth can influence results.
Precision Digestive also describes small-bowel aspirate culture as a different reference method. This involves culturing a sample from the small bowel. The article notes that it is invasive, helping explain why breath testing is used in practice. Presenting another method does not make it a routine requirement for everyone with IBS symptoms.
These limits belong in the same conversation as the test's purpose. A clinician needs to explain how the result will be interpreted alongside symptoms and what questions will remain afterward. The useful outcome is a clearer clinical assessment, not simply a positive or negative label detached from the reason testing was considered.
For an individual reader, the practical question is therefore specific: how would this investigation help explain the recurring problem being assessed? That keeps the discussion focused on the person's situation rather than treating a test name as the answer in itself.
For people living with recurring digestive discomfort, the clearest next step supported by the explainer is a discussion with a qualified healthcare professional. That conversation can start with the experience itself rather than a diagnosis selected from competing online descriptions.
Useful points to bring into that discussion include:
The dietary implication is restraint in interpreting the headline, not a new restriction. This explainer is not a reason to build a food plan around a self-assigned SIBO or IBS label. Decisions about an individual's diet belong in the context of their symptoms and qualified clinical advice.
The realistic takeaway is that similar symptoms deserve careful interpretation before they become a reason to change everyday eating. The news adds clarity to the diagnostic conversation. It does not supply a universal menu or a single testing pathway for everyone who feels bloated.
Similar symptoms make the SIBO and IBS distinction a clinical question rather than a label to choose alone. DigestGenius addresses confusion about bloating and bowel regularity with free articles and in-depth resources that explain digestive research in clear language, giving adults educational context for conversations about their digestive patterns.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.



Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog